Efficacy and safety of artesunate-amodiaquine and artemether-lumefantrine among children 6 to 59 months for the treatment of uncomplicated Plasmodium falciparum in Chad

Proportion of treatment failures (early treatment failure + late clinical failure+late parasitological failure). This is a composite primary outcome. Enrolled patients were monitored for clinical and parasitological (using microscopy) responses. Treatment outcomes was classified according to the latest WHO protocol.

Efficacy and safety of artesunate-amodiaquine and artemether-lumefantrine for the treatment of uncomplicated P. falciparum malaria infections in children aged 6 to 59 months in Chad. Artemether-lumefantrine or artesunate-amodiaquine was given under direct supervision and clinical and parasitological parameters were monitored for 28 days to establish proportion of patients with PCR corrected treatment failure and frequency of adverse events. Mutations in K13, mdr1, crt, dhfr an dhps genes were investigated on day 0 samples.